Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine Spray for Hemodynamic Response in CABG Intubation
NCT03304431Phase 4Completed
- Sponsor
- Bolu Abant Izzet Baysal University
- Start
- May 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of lidocaine 10% oropharyngeal spray in coronary artery disease (CAD) (2 arms), sponsored by Bolu Abant Izzet Baysal University. Primary endpoints: Corrected QT Interval, QT Dispersion and 1 more. Started May 2017; status: completed.
02
Drugs
lidocaine 10% oropharyngeal spray
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03304431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03304431.